Becton Dickinson insider files Form 144 to sell 58 RSU shares on NYSE
Rhea-AI Filing Summary
Becton Dickinson & Co. (BDX) Form 144 shows a proposed sale of 58 shares of common stock through Morgan Stanley Smith Barney with an aggregate market value of $10,474.22 and an approximate sale date of 09/26/2025 on the NYSE. The shares were acquired as Restricted Stock Units on 08/20/2025. The filing also discloses a prior 10b5-1 sale of 57 shares on 08/22/2025 with gross proceeds of $11,285.43. The form lists total shares outstanding as 286,627,469. Several filer contact fields and issuer identification fields are blank in the provided content.
Positive
- Securities were acquired as Restricted Stock Units, clearly dated 08/20/2025 providing a clear acquisition record
- Broker and marketplace disclosed: Morgan Stanley Smith Barney and NYSE are named for the proposed sale
- Prior 10b5-1 sale disclosed (57 shares on 08/22/2025), which can indicate pre-planned trading activity
Negative
- Key filer and issuer identification fields are blank in the provided extract (CIK/CCC, issuer SEC file number, issuer address), reducing traceability
- No plan adoption or signature details shown in the extract if relying on a Rule 10b5-1 plan, which limits compliance verification
- Very small transaction size may be immaterial to investors, offering limited information value
Insights
TL;DR: Routine insider disposition; very small position size relative to company float, likely non-material to shareholders.
The filing documents a proposed sale of 58 shares acquired as RSUs two weeks earlier. The transaction size and stated aggregate value are minor relative to the reported 286,627,469 shares outstanding, indicating limited market impact. The presence of a near-term prior 10b5-1 sale (57 shares on 08/22/2025) suggests the insider has been executing small dispositions. No earnings or operational data are disclosed here to alter the investment thesis.
TL;DR: Filing appears routine but lacks some identifying contact and issuer detail in the provided extract.
The form identifies the broker and transaction details but the provided tables omit filer CIK/CCC and issuer address/SEC file number fields, which are typically required for full provenance and regulatory tracking. The remarks section includes the standard Rule 144 and 10b5-1 attestations, but no plan adoption date or signature details are present in the extract; if relying on a trading plan, that date should be disclosed. Missing fields limit completeness for compliance review.